Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Danaher Corporation diseña, fabrica y comercializa productos y servicios profesionales, médicos, de investigación e industriales en los Estados Unidos, China e internacionalmente. La empresa opera a través de los segmentos de biotecnología, ciencias biológicas y diagnóstico.
Traducido automáticamente
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $25.1B | $24.6B | $23.9B | $23.9B | $26.6B | $29.5B | $22.3B | $17.9B | $17.0B | $18.3B | $16.9B | $14.4B | $19.9B | $19.1B | $18.3B | $16.1B | $13.2B | $11.2B | $12.7B | $11.0B | $9.6B |
| Beneficio bruto | $14.7B | $15.0B | $14.2B | $14.0B | $16.2B | $18.0B | $12.5B | $10.0B | $9.5B | $10.2B | $9.4B | $7.9B | $10.5B | $10.0B | $9.4B | $8.2B | $6.6B | $5.4B | $6.0B | $5.0B | $4.2B |
| % de margen bruto | 58.5% | 60.9% | 59.5% | 58.7% | 60.8% | 61.0% | 56.0% | 55.7% | 55.8% | 55.8% | 55.6% | 54.8% | 52.7% | 52.2% | 51.7% | 51.2% | 50.2% | 48.3% | 47.0% | 45.7% | 44.2% |
| Ingresos operativos (EBIT) | $5.1B | $5.1B | $5.2B | $5.2B | $7.5B | $8.1B | $4.3B | $3.4B | $3.1B | $3.1B | $3.0B | $2.4B | $3.6B | $3.4B | $3.2B | $2.7B | $2.2B | $1.7B | $2.0B | $1.7B | $1.5B |
| % de margen operativo | 20.4% | 20.9% | 21.7% | 21.8% | 28.3% | 27.3% | 19.4% | 18.8% | 18.0% | 17.2% | 17.7% | 16.8% | 18.1% | 17.6% | 17.5% | 17.0% | 16.9% | 15.5% | 15.4% | 15.7% | 15.7% |
| Ingresos netos | $4.0B | $3.6B | $3.9B | $4.7B | $7.2B | $6.4B | $3.6B | $2.6B | $2.7B | $2.5B | $2.6B | $2.6B | $2.6B | $2.7B | $2.3B | $2.0B | $1.8B | $1.2B | $1.3B | $1.2B | $1.1B |
| % de margen neto | 16.0% | 14.7% | 16.3% | 19.9% | 27.1% | 21.8% | 16.4% | 14.3% | 15.6% | 13.6% | 15.1% | 18.0% | 13.1% | 14.1% | 12.6% | 12.2% | 13.6% | 10.3% | 10.4% | 11.1% | 11.7% |
| EBITDA | $7.2B | $6.9B | $7.3B | $5.2B | $9.5B | $10.0B | $6.5B | $4.6B | $4.3B | $4.3B | $3.9B | $3.1B | $4.5B | $4.6B | $4.0B | $3.2B | $2.9B | $1.9B | $2.2B | $2.0B | $1.7B |
| Beneficio por acción (EPS) | $5.63 | $5.08 | $5.29 | $6.38 | $9.78 | $8.73 | $5.07 | $3.52 | $3.73 | $3.53 | $3.65 | $3.67 | $3.63 | $3.79 | $3.22 | $2.81 | $2.62 | $1.72 | $1.96 | $1.85 | $1.72 |
| Acciones en circulación (M) | 708M | 711M | 737M | 743M | 737M | 737M | 719M | 726M | 710M | 706M | 700M | 708M | 716M | 711M | 713M | 701M | 683M | 671M | 672M | 659M | 651M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de DHR. /companies/us/DHR
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms